Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
08/2005
08/17/2005EP1562618A1 Cyclooxygenase-2 inhibitory withanolide compositions and method
08/17/2005EP1562617A1 New alpha-glucosidase inhibitors from a natural source
08/17/2005EP1562615A1 Oral and dental composition
08/17/2005EP1562614A1 High affinity receptors for helicobacter pylori and use thereof
08/17/2005EP1562613A1 Nadh/nadph-containing compound
08/17/2005EP1562612A1 Combination product of inhibitor of the src family of non-receptor tyrosine kinases and gemcitabine
08/17/2005EP1562610A1 Combination therapy with gemcitabine and zd6126
08/17/2005EP1562609A1 Inositolized phospholipids
08/17/2005EP1562608A2 Methods of using substituted tetracycline compounds to modulate rna
08/17/2005EP1562607A1 Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
08/17/2005EP1562606A2 Methods of using vitamin d compounds in the treatment of myelodysplastic syndromes
08/17/2005EP1562605A2 Compounds for modulation of cholesterol transport
08/17/2005EP1562604A1 Prostaglandin compounds for the treatment of obesity
08/17/2005EP1562603A2 Novel medicaments for the treatment of chronic obstructive pulmonary diseases
08/17/2005EP1562602A2 Immediate release topical pharmaceutical formulation for enhancement of female sexual desire and responsiveness
08/17/2005EP1562601A1 Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
08/17/2005EP1562600A2 Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders
08/17/2005EP1562598A2 Derivatives of gambogic acid and analogs as activators of caspases and inducers of apoptosis
08/17/2005EP1562597A2 Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration
08/17/2005EP1562594A2 Methylene-bridged selective androgen receptor modulators and methods of use thereof
08/17/2005EP1562593A2 Topoisomerase-targeting agents
08/17/2005EP1562592A2 Histone deacetylase inhibitors for treating degenerative diseases of the eye
08/17/2005EP1562591A1 Treatment of mesothelioma
08/17/2005EP1562590A2 Compounds, methods and devices for inhibiting neoproliferative changes in blood vessel walls
08/17/2005EP1562589A2 Diaminotriazoles useful as inhibitors of protein kinases
08/17/2005EP1562588A2 Use of pde4 inhibitors as adjunct therapy for psychiatric disorders
08/17/2005EP1562587A2 Novel compositions and methods for the treatment of immune related diseases
08/17/2005EP1562586A2 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
08/17/2005EP1562585A1 Daily melatonin dosing units
08/17/2005EP1562582A1 Cholesterol absorption inhibitors for the treatment of demyelination
08/17/2005EP1562581A2 Pharmaceutical composition comprising cannabinoids for the treatment of pain andsleep disorders
08/17/2005EP1562579A1 Therapeutic delivery of carbon monoxide
08/17/2005EP1562578A1 Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
08/17/2005EP1562577A1 Acetyl-l-carnitine for the prevention and/or treatment of peripheral neuropathies induced by anticancer agents
08/17/2005EP1562576A1 Enhancement of alcohol metabolism
08/17/2005EP1562575A1 Fused cycloalkyl amides and acids and their therapeutic applications for the treatment of i.a. epilepsy
08/17/2005EP1562574A1 2-oxo-ethanesulfonamide derivates
08/17/2005EP1562573A1 Pharmaceutical pellets comprising tamsulosin and a process for making the same
08/17/2005EP1562572A2 Pharmaceutical solutions of modafinil compounds
08/17/2005EP1562571A1 Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
08/17/2005EP1562570A1 Treatment of amyotrophic lateral sclerosis with nimesulide
08/17/2005EP1562569A1 Antifungal medicaments comprising arylamidine derivatives
08/17/2005EP1562568A1 Treatment of heaves
08/17/2005EP1562567A1 Combination of selected analgesics and cox-ii inhibitors
08/17/2005EP1562566A1 Analgesic compositions comprising nmda receptor antagonists and benzalkonium chloride
08/17/2005EP1562564A2 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
08/17/2005EP1562563A2 Methods for treatment of thiol-containing compound deficient conditions
08/17/2005EP1562560A1 Modified release composition comprising a short-acting hypnotic for treatment of sleep disorders
08/17/2005EP1562556A2 Pharmaceutical compositions and dosage forms of thalidomide
08/17/2005EP1562555A2 Sustained release l-arginine formulations and methods of manufacture and use
08/17/2005EP1562554A1 A method for normalizing insulin levels
08/17/2005EP1562552A1 Controlled release carvedilol compositions
08/17/2005EP1562548A1 Oral testosterone delivery system with improved sustained release
08/17/2005EP1562547A1 Method of stimulating hair growth using benzopyrans
08/17/2005EP1562546A1 Depot formulations of arylheterocyclic active agents in the form of a suspension
08/17/2005EP1562531A2 Topical skin care composition
08/17/2005EP1562492A1 Method and apparatus for the detection and occlusion of blood vessels
08/17/2005EP1562489A2 Stabilized polyester/cyanoacrylate tissue adhesive formulation
08/17/2005EP1562449A1 Composition for enhancing physical performance
08/17/2005EP1562447A1 Antioxidative compositions
08/17/2005EP1562422A2 Compositions and methods for prolonging survival of platelets
08/17/2005EP1499594B1 Process for the preparation of 7-substituted-3-quinoline and 3-quinol-4-one carbonitriles
08/17/2005EP1496889B1 Stabilized ascorbic acid derivatives
08/17/2005EP1485385B1 Pyrazolopyrimidine and pyrazolotriazine derivatives and pharmaceutical compositions containing them
08/17/2005EP1466174A4 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
08/17/2005EP1463725B1 Process and intermediates for pyridazinone antidiabetic agents
08/17/2005EP1436380B1 Composition comprising a lactobacillus strain and uses thereof
08/17/2005EP1411895B1 Oral pharmaceutical composition comprising an active principle capable of being subjected to high effect during its first passage through the intestine
08/17/2005EP1389196A4 Three-step conversion of protected taxane ester to paclitaxel
08/17/2005EP1377558B1 [1,4]-diazepane-1-carboxylic acid derivatives, process for their preparation and their use as tachykinin antagonists
08/17/2005EP1351680B8 Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity
08/17/2005EP1351676B1 Use of isovaleryl l-carnitine for the preparation of a medicament for the prevention and cure of osteoporosis
08/17/2005EP1343761B1 Piperidine mch antagonists and their use in the treatment of obesity
08/17/2005EP1326609B1 Stable oral formulation containing benzimidazole derivative
08/17/2005EP1319397B1 Suppositories sustained in the lower rectum
08/17/2005EP1315496B1 The treatment of inflammatory disorders
08/17/2005EP1311256B1 Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
08/17/2005EP1294372B1 Dry powder formulation comprising racecadotril
08/17/2005EP1289951B1 Growth hormone secretagogues
08/17/2005EP1289520B1 Pharmaceutical compositions for the treatment of depression comprising famotidine
08/17/2005EP1282418B1 Use of pyrazole derivatives for treating infertility
08/17/2005EP1280757B1 New gamma selective retinoids
08/17/2005EP1267642A4 Starch sub-types and lipid metabolism
08/17/2005EP1266887B1 Indenoindoline derivatives, their process of preparation and pharmaceutical compositions containing them
08/17/2005EP1265893B1 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
08/17/2005EP1256575B1 Phenoxyalkylamine derivatives useful as opioid delta receptor agonists
08/17/2005EP1253853A4 Method for classifying and treating physiologic brain imbalances using quantitative eeg
08/17/2005EP1248651B1 Product comprising a heterotrimeric g protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
08/17/2005EP1237552B1 Combination of lumilysergol and riluzole for preventing and/or treating motoneuronal diseases
08/17/2005EP1236724B1 Neutralizing agent for toxin of microorganism belonging to the genus clostridium
08/17/2005EP1225913B1 Use of nitric oxide for the treatment of airway constriction
08/17/2005EP1200446B1 OXATHIEPINO 6,5- i b /i ]DIHYDROPYRIDINES, AND RELATED COMPOSITIONS AND METHODS
08/17/2005EP1196397B1 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases
08/17/2005EP1194141B1 Antiviral therapy
08/17/2005EP1192164B1 Thieno- and furopyrimidine derivatives as a2a-receptor antagonists
08/17/2005EP1185268B1 The therapeutic use of d-threo-methylphenidate for the treatment of attention-deficit hyperactivity disorder
08/17/2005EP1181274A4 Iminocyclitol inhibitors of hexoaminidase and glycosidase
08/17/2005EP1179984B1 Process for manufacturing a product for enhancing immune response in companion animals using a combination of antioxidants
08/17/2005EP1173178B1 Composition comprising apomorphine and sildenafil and the use thereof for the treatment of erectile dysfunction
08/17/2005EP1161240B1 N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
1 ... 4577 4578 4579 4580 4581 4582 4583 4584 4585 4586 4587 4588 4589 4590 4591 4592 4593 4594 4595 4596 4597 ... 7860